Hepatitis

This study looks at whether a medicine called peginterferon alfa, alone or with other antivirals, can clear the hepatitis B surface antigen from the blood. A total of 10,000 adults aged 18-65 who have used interferon before and still have low antigen levels will take the treatmen…

This early-stage trial will test an experimental vaccine against hepatitis C (HCV) in 27 healthy adults. The main goal is to see if the vaccine is safe and to measure the immune response it triggers. Participants will receive three shots over 24 weeks and be closely monitored for…

This study tests a drug called foscenvivint in people with liver cirrhosis caused by HIV and hepatitis C co-infection who also have hemophilia. Participants receive the drug once a week for 24 weeks. Researchers will check if the drug improves liver function and is safe to use.

This study tests whether adding a Mediterranean-style meal delivery program to resmetirom therapy improves liver health more than resmetirom alone. It involves 120 adults with non-cirrhotic MASH who are starting resmetirom. Participants either receive the drug plus 10 medically t…

This early-stage trial tests an injection called TVAX-028 in adults with chronic hepatitis B. The study checks if the drug is safe and how the body processes it. Participants receive either TVAX-028 with an adjuvant or the adjuvant alone, at different dose levels. The goal is to …

This trial tests whether ursodeoxycholic acid (UDCA), a bile acid supplement, can speed up liver regeneration in adults receiving a living-donor liver transplant. Participants take UDCA or a placebo starting at least 10 days before surgery and continuing for 10 days after. Resear…

This study tests whether combining mycophenolate mofetil (MMF) with prednisone can better treat liver inflammation caused by checkpoint inhibitor cancer drugs. The trial includes adults with moderate to severe immune-related hepatitis who need to pause their cancer therapy. The m…

This clinical trial tests two experimental injections, HRS-4729 and HRS9531, in adults with metabolic dysfunction-associated steatohepatitis (MASH), a serious liver condition linked to obesity. The study involves 160 participants who receive either the drug or a placebo for 52 we…

This study tests whether a combined approach—offering HIV PrEP (pills or injections) and STI prevention (doxycycline after sex) along with smartphone tools—helps young men at high risk stay protected. About 400 men aged 18-29 who have sex with men will be followed for a year to s…

This phase 2 trial tests an experimental drug called AHB-137 in 70 adults with chronic hepatitis B who are already on antiviral pills. The drug is given as a shot under the skin. The goal is to see if it can lower the virus to undetectable levels and allow some people to stop the…

This Phase 3 trial tests whether the drug HSK31679 can safely improve liver health in 400 adults with MASH, a serious fatty liver disease. Participants will take either the drug or a placebo daily for about a year. The main goals are to see if the drug can reverse liver inflammat…

This phase 2 trial tests whether ursodeoxycholic acid (UDCA), a drug already used for other liver conditions, can treat cholestatic hepatitis—a liver inflammation caused by immunotherapy—better than standard steroids. About 94 adults with cancer (excluding liver cancer) who devel…

This study looks at whether adding L-carnitine, a natural substance, to standard care can improve outcomes for critically ill adults with liver disease in the ICU. About 58 participants with conditions like liver failure or severe infections will be enrolled. Researchers will tra…

This study tests an experimental drug called ALN-CIDEB in 150 adults with MASH, a serious liver disease involving fat buildup and scarring. The goal is to see if the drug can reduce liver fat, injury, and scarring compared to a placebo. Participants will receive either the drug o…

This phase 2 trial tests an injection called AHB-137 in adults with chronic hepatitis B who have not yet received treatment. The study compares AHB-137 to a placebo to see if it can lower the amount of hepatitis B virus in the blood and reduce a key marker of infection (HBsAg). P…

This Phase 2 trial tests an injection called AHB-171 in 138 people with chronic hepatitis B. The goal is to see if it can lower hepatitis B surface antigen and viral DNA to very low levels, potentially leading to a functional cure. Participants include those who have never been t…

This study tests a treatment called extracorporeal photopheresis (ECP) for people with advanced melanoma who develop severe colitis or hepatitis from immunotherapy. ECP filters a patient's blood, treats it with a light-activated drug, and returns it to the body. The trial compare…

This Phase 2 trial tests a new drug called QL2401 in 132 adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate liver scarring. Participants receive weekly injections of either QL2401 or a placebo for 48 weeks. The main goal is to see if the drug reduces…

This early-phase study tests a new injectable drug called AHB-171 in 144 adults with chronic hepatitis B. The main goals are to check the drug's safety and how the body processes it. Some participants will also take standard oral antivirals. The study is not yet recruiting.

This study tests an experimental injection called HRS-5635 in adults with chronic hepatitis B whose virus is already controlled by daily pills. The goal is to see if the injection can help the body clear the virus so patients can safely stop all hepatitis B medications. About 540…

This early-stage study tests a single injection of AHB-137 in 32 people with chronic hepatitis B, some with mild to moderate liver dysfunction and some with normal liver function. Researchers will measure how the drug moves through the body and check for safety issues. The goal i…

This study tests a drug called inebilizumab in 180 adults with autoimmune hepatitis, a condition where the immune system attacks the liver. The goal is to see if the drug can reduce liver inflammation and allow patients to take lower doses of steroids. Participants will receive e…

This study compares remote robotic liver surgery to local robotic surgery to see if the remote approach is just as safe and effective. About 148 adults with liver disease will be randomly assigned to one of the two types of surgery. Researchers will track complications, recovery,…

This early-stage trial is testing a new drug called ACT500 in 24 people who have both fatty liver disease and chronic hepatitis B. The main goal is to check the drug's safety and how the body processes it at different doses. Participants will take ACT500 or a placebo daily, and r…

This phase 3 trial tests a new drug called GST-HG141 (Nairecovir) combined with standard antivirals in 576 adults with chronic hepatitis B. Participants have already completed 48 weeks of treatment in an earlier study. The goal is to see if the combination is safe and helps keep …

This study tests whether a one-visit, point-of-care test and treat approach helps more people with HIV, hepatitis B, or hepatitis C complete hepatitis C treatment within 24 weeks compared to standard care. About 1,280 participants will be randomly assigned to either the simplifie…

This early-phase study will test whether adding peginterferon alfa-2b to standard antiviral drugs can help prevent hepatitis B-related liver cancer from coming back after surgery. About 156 adults aged 18 to 65 will receive either the combination or antivirals alone. Researchers …

This study tests a new care model for veterans with opioid use disorder that combines infectious disease screening and treatment with their usual medication-assisted therapy in a single appointment. The goal is to make it easier for veterans to get tested and treated for infectio…

This study tests whether adding Babao Dan Capsule (a traditional Chinese medicine) to standard antiviral treatment can lower the chance of developing liver cancer in people with hepatitis B-related cirrhosis who are at high risk. About 1,034 adults aged 18-65 with a specific TCM …

This study tests whether a medicine called ursodeoxycholic acid (UDCA) can help lower bilirubin levels in people with acute viral hepatitis (types A or E). Bilirubin is a waste product that builds up when the liver is inflamed, causing jaundice. The trial will compare 88 adults w…

This study looks at whether combining a probiotic supplement with resistance exercise can help people with metabolic fatty liver disease (MAFLD/NAFLD). Researchers will measure changes in liver fat using MRI over 12 weeks. The goal is to find out which patients benefit most based…

This study tests an AI-powered assistant (Union-Agent) designed to encourage people with chronic hepatitis B who have been diagnosed but not yet treated to start antiviral medication. The study will enroll 2000 adults in China who are eligible for treatment but haven't started. T…

This early-stage study tests a new drug called OPK-88006 in 30 people, first in healthy volunteers and then in those with MASH (a serious liver condition). The goal is to check safety, how the drug moves through the body, and early signs of liver improvement. Results will help de…

This study tests a new drug called SNP-610 for people with non-alcoholic steatohepatitis (NASH), a type of fatty liver disease. About 80 adults will receive either the drug or a placebo for 3 months. The main goal is to see if SNP-610 lowers liver enzyme levels and reduces liver …

This early-stage study tests a new oral drug called ACT500 in 24 adults with fatty liver disease (MASLD). The main goal is to check safety and how the drug moves through the body. Participants take one pill daily in different dose groups. The study does not aim to cure the diseas…

This study tests whether adding a traditional Chinese medicine called Biejia-Ruangan compound to standard antiviral therapy can lower the chance of developing liver cancer in people with hepatitis B-related cirrhosis. About 1,034 high-risk adults (based on a special score) will b…

This study tests whether giving financial rewards based on a blood test can help people with alcohol-related liver disease stop or reduce drinking. The blood test detects alcohol use over the past month. 90 adults will be randomly assigned to either a rewards group that gets esca…

This study tests a temporary device placed in the upper small intestine to help control type 2 diabetes and obesity. The implant stays for 6 months and is then removed. Researchers will check if it lowers blood sugar (HbA1c), helps with weight loss, and improves liver health in p…

This early-phase study tests a new drug called WGb-0301 for people with autoimmune diseases (like lupus or autoimmune hepatitis) that haven't responded to standard treatments. The drug uses mRNA technology to target and clear certain immune cells (B cells) that are causing the di…

This study tests whether giving two antiviral drugs—entecavir followed by pegylated interferon—can help children aged 3 to 6 with chronic hepatitis B achieve a functional cure (clearing the virus from the blood). About 80 children will be randomly assigned to receive either entec…

This study tests whether adding pegylated interferon to entecavir helps young children (ages 3-6) with chronic hepatitis B achieve a functional cure, meaning the virus becomes undetectable. Sixty children will receive either entecavir alone or entecavir followed by the combinatio…

This study tests whether betaine, a natural substance found in the body, can reduce liver injury in people with MASH (a serious fatty liver disease). Seventy participants will take either betaine or placebo pills for 24 weeks, with follow-up for another 24 weeks. The main goal is…

This Phase 3 trial tests a drug called hepalatide (L47) in 150 people with chronic hepatitis D, a serious liver disease. Participants receive either the drug or a placebo daily for 48 weeks. The goal is to see if hepalatide can lower virus levels and normalize liver enzymes. Afte…

This Phase 3 trial tests an injection called TVAX-008 for people with chronic hepatitis B. About 630 adults who have been on antiviral therapy for at least 6 months will receive either TVAX-008, a placebo, or an active comparator. The goal is to see if the treatment can clear hep…

This study tests two blood products used to control bleeding during liver transplant surgery. It compares a newer product, Intercept Fibrinogen Complex, to standard cryoprecipitate. The goal is to see if the newer product works as well or better at stopping bleeding. The study wi…

This phase 2 trial will enroll 82 stable liver transplant recipients with chronic hepatitis B to see if switching to entecavir orally disintegrating tablets (ETV-ODT) is safe and helps preserve kidney function. Participants will take the drug daily for 48 weeks, and researchers w…

This study will offer free hepatitis B testing to nearly 240,000 adults in Phichit, Thailand, who were born before 1992 and may have been infected before vaccines were available. Those who test positive will receive care and daily medication to control the virus and prevent liver…

This study compares two antiviral strategies—one using a single drug (TAF) and the other starting with two drugs (entecavir plus TAF) then switching to TAF alone—in 120 people with advanced hepatitis B-related liver cancer who are also receiving immunotherapy. The main goal is to…

This study tests whether a weekly injection of pegylated interferon alfa-2b for 48 weeks can help children and teens (ages 3–17) with chronic hepatitis B achieve a functional cure. The treatment group will be compared to an observation group receiving no drug or standard antivira…

This early-stage trial tests a new therapeutic vaccine (Hepadvax) in 40 adults with chronic hepatitis B. The vaccine is designed to boost the immune system to control or possibly clear the virus. Researchers will monitor safety, viral load, and immune responses compared to a stan…

This study tests whether empagliflozin (a diabetes drug) works better than statins for treating non-alcoholic fatty liver disease (NAFLD) and its more severe form, NASH. 400 obese, diabetic adults with NAFLD/NASH will take one of five drug combinations daily for 3 months. Researc…

This study tests whether adding a traditional Chinese medicine granule (Huazhi Rougan) to standard antibiotics can better treat both H. pylori infection and metabolic-associated fatty liver disease (MASH). About 286 adults with both conditions will receive either the herbal granu…

This study will test a new rapid device called TruPlex that checks for HIV, Hepatitis B, and Syphilis using a single fingerstick blood sample. About 500 adults at risk for these infections will take part. Researchers want to see if the test is accurate and easy for trained staff …

This study will test a new computer tool that helps emergency doctors spot patients at high risk for hepatitis C and HIV. The tool uses a machine learning algorithm to analyze patient data and pops up an alert for the doctor. Researchers will compare this targeted screening with …

This study checks if a simpler way to collect blood samples works as well as the standard method for the HepQuant DuO liver test. The test involves drinking a natural substance and taking blood samples 20 and 60 minutes later. Researchers will compare different blood collection t…

This study will check if a new device called MagIA H3S can accurately detect HIV, hepatitis B, hepatitis C, and syphilis in pregnant women in the Democratic Republic of the Congo. About 7,500 pregnant women will take part. The goal is to see if this quick test works as well as st…

This study tests a near-infrared spectroscopy device that scans the liver with light to diagnose and measure fatty liver disease. Researchers aim to see if it can accurately detect fat levels above 5% and 30%, which are important for liver transplant decisions. The study will inc…

This study looks at whether a new finger-stick test for hepatitis C, which gives results in about an hour, is acceptable to patients in the emergency department. Researchers will enroll 200 adults who have tested positive for hepatitis C antibodies but don't know if they have an …

This study looks at whether measuring a protein called TREM-1 in liver tissue can help doctors better predict how patients with severe alcoholic hepatitis will do. Researchers will compare TREM-1 levels in 300 people—half with alcoholic hepatitis and half with other liver disease…

This study will test whether offering HIV prevention medication, routine STI testing, and a preventive antibiotic at retail pharmacies helps young women avoid infections. About 720 women aged 15 to 24 who visit pharmacies for birth control will take part. Researchers will check h…

This study in Zimbabwe will screen women of childbearing age and high school students for HPV and Hepatitis B, then offer vaccines to those who are eligible. It also includes cognitive behavioral therapy for mental health issues. The goal is to see if this combined approach can p…

This study investigates how the experimental cancer drug atirmociclib is processed by the body in people with mild, moderate, or severe liver disease compared to those with healthy livers. Participants receive a single oral dose of the drug, and blood samples are taken over time …

This French study will collect medical data and biological samples from 800 people with autoimmune liver diseases. Researchers hope to identify new markers that explain why some patients respond well to treatment while others do not. The goal is to better understand the immune me…

This study aims to create a score that predicts the risk of infection within 30 days after a liver transplant. Researchers will collect blood samples from 279 liver transplant patients before and after surgery to measure immune markers. The goal is to combine these markers with o…

This study looks at two types of liver disease — autoimmune hepatitis and non-alcoholic fatty liver disease — to see if fats in blood cells and tiny particles called extracellular vesicles differ between them. Researchers will collect blood samples from 24 adults and analyze thes…

This phase 1 trial investigates how mild, moderate, and severe liver impairment affects the way the body processes a single inhaled dose of treprostinil palmitil, a drug used for certain lung conditions. The study enrolls about 30 adults with varying levels of liver function and …

This study tests new MRI techniques to measure blood flow and tissue details in the liver. Researchers will scan 110 people, including healthy volunteers and those with chronic liver disease or fibrosis, to see if these scans can reliably detect liver damage. The goal is to devel…

This pilot study tests a one-time 'booster' session for people who inject drugs and their injecting partners, given right after finishing hepatitis C treatment. The session helps them set health goals, identify barriers, and improve communication to stay engaged in ongoing health…

This study looks at 2,500 people newly diagnosed with hepatitis C in France. Researchers will use existing medical data to map the different virus types and subtypes, including rare ones. The goal is to understand which types are most common and why some treatments fail, helping …

This early-stage study is testing a new medicine for overweight and obesity. The main goal is to see how the drug behaves in people with different levels of liver function, from normal to severely reduced. About 35 adults aged 18-80 will take a single dose, and researchers will m…

This study looks at whether lifestyle changes can reduce the risk of liver cancer in people already at high risk. Researchers will track changes in bile acids, gut bacteria, and liver health in 90 adults aged 50-90. The goal is to see if simple adjustments can make a lasting diff…

This early-stage study looks at how a single 25 mg dose of VC005 tablets behaves in people with mild or moderate liver impairment compared to healthy volunteers. The goal is to measure drug levels and safety. 24 participants will take one dose and be monitored closely.

This study tests whether a pop-up alert in electronic medical records can help primary care doctors order screening for HIV, hepatitis B, and hepatitis C all at once. About 50 primary care providers will participate, and their patient visits will be randomly assigned to either se…

This study will follow 1,000 adults who have liver or bile duct surgery at one hospital in Italy. Researchers will track complications, survival, and cancer recurrence for up to 5 years. The goal is to better understand what affects recovery and long-term health after these opera…

This early-stage study will give a single dose of MDR-001, a GLP-1 receptor agonist tablet, to 32 people: some with mild or moderate liver impairment and some with healthy livers. Researchers want to see how the drug moves through the body and if it is safe in people with liver i…

This early-stage study looks at how the drug anecatibin fumarate is processed in the body of people with and without liver problems. It will include 24 adults with lung cancer. The goal is to understand safety and drug levels, not to test if the drug works.

This study will follow 352 pregnant women with chronic hepatitis B to see how often their liver enzymes rise after giving birth. Researchers want to find out what factors predict these spikes, especially comparing those who took antiviral drugs during pregnancy to those who did n…

This study looks at how satisfied young people and those with low incomes are with free HIV and STI testing and counselling in Lucerne and Zurich. Around 1,800 participants will fill out a questionnaire after their visit. The goal is to see if these free services meet people's ne…

This early-stage study looks at how the drug GS1-144 moves through the bodies of women with and without liver problems. About 24 women aged 18 to 70 will take part. The goal is to measure drug levels and see if liver function affects them. No treatment is being tested.

This study looks at how a 12-week exercise program (strength and aerobic training twice a week) affects liver fat, inflammation, and scarring in people with metabolic fatty liver disease. It compares results between older adults (70+) and middle-aged adults (40-60), as well as be…

This study looks at how the hepatitis B virus changes over time in people taking antiviral drugs. Researchers will analyze blood samples from 700 adults in Turkey to see if the virus becomes resistant to treatment. The goal is to help doctors choose the best medications for each …

This early-stage study looks at how the drug buagafuran (AF-5) behaves in people with liver impairment compared to those with normal liver function. Twenty-four adults will receive a single 30 mg dose, and researchers will measure drug levels in the blood and monitor safety. The …

This study aims to create an artificial intelligence (AI) system that can combine medical images (like CT and MRI scans) with patient records and lab results to help doctors more accurately diagnose diseases of the liver, gallbladder, and pancreas. The researchers will use data f…

This study will follow 5,160 pregnant women in France who have HIV, hepatitis B, hepatitis C, or an arbovirus infection (like Zika or dengue), along with their children, for up to 7 years. Researchers want to learn how these viruses and their treatments affect pregnancy, the moth…

This study looks at how the drug hydronidone moves through the body in people with different levels of liver function. Thirty adults with either normal liver function or varying degrees of liver impairment will take a single dose of the drug. The goal is to understand how liver h…

This study looks at how well telemedicine works to treat hepatitis C in people who are already getting care at opioid treatment programs. Researchers will review medical records from 200 patients to see how many start and finish their hepatitis C treatment. The goal is to make it…

This study will collect blood samples from 30,000 adults in the UK with various health conditions, including blood clots, infections, heart disease, diabetes, and more. The samples will be used to develop and fine-tune new diagnostic tests for the cobas® lumira device, which allo…

This study tests whether digital messages created by sex trafficking survivors can encourage more HIV, STI, and hepatitis C testing, as well as use of overdose prevention kits. About 368 survivors in New York City will be randomly assigned to see either survivor-made messages or …

This study looks at whether a rapid fingerstick test that gives results in 10-20 minutes can help more people get screened for HIV, hepatitis C, and syphilis during mobile clinic visits. About 200 patients of the WVU Street Medicine team can choose the rapid test, a traditional b…

This observational study looks at data and samples from 220 people with hepatitis D (HDV) who are already taking the medication bulevirtide. Researchers want to see how well the drug works over time and find markers that predict a good response. The goal is to improve monitoring …

This study follows 600 Chinese children who received standard vaccines against polio, measles, mumps, rubella, and hepatitis A. Researchers will test their blood to see if protective antibodies remain 5 years after vaccination. The goal is to understand how long vaccine protectio…

This study will screen up to 10,000 adults aged 18-75 who are overweight or have metabolic issues like high blood sugar or cholesterol. Researchers will use questionnaires, blood tests, and liver ultrasounds to find out how common fatty liver disease is and what factors increase …

This early-stage study tests the safety and tolerability of a new drug called QL2401 in 70 healthy Chinese adults aged 18 to 45. Participants receive either the drug or a placebo to see how the body handles it. The goal is to gather initial safety data before testing in people wi…

This study looks at stored liver biopsy samples from 30 people with MASH (a fatty liver disease) to see if a protein test can predict who will develop liver cancer within 15 years. Half of the participants later got liver cancer, and half did not. Researchers will compare the pro…

This early-stage trial will test a new drug called hydronidone, which is being developed for liver fibrosis caused by hepatitis B. Since patients often need to take antiviral drugs for hepatitis B, researchers want to see if hydronidone can be taken safely alongside four common a…

This study will look at 80 pregnant women with signs of liver issues, such as high liver enzymes or bilirubin, to find out which liver disorders are most common and how they affect both mother and baby. Researchers will track changes in liver health over time using blood tests an…

This pilot study will test whether an 8-session telehealth program can help people who inject drugs in the rural South build coping skills and resilience. The goal is to improve access to HIV prevention (PrEP), hepatitis C treatment, and medication for opioid use disorder. The st…

This study is testing a new program to help men living with HIV in Uganda feel more comfortable telling their sexual partners about their HIV status. The program includes education, counseling, and practice conversations. Researchers want to see if it helps more men share their s…

This study will compare two types of liver transplants: auxiliary (where part of the patient's own liver is left in place) and living donor (where a portion of a donor's liver is used). Researchers will track 100 patients to see which approach leads to better survival, fewer comp…

This study will enroll 2,000 Egyptian patients with chronic hepatitis B to find out how common antiviral drug resistance is and what factors make it more likely. Researchers will look at patients taking common antiviral drugs like tenofovir, entecavir, or lamivudine. The goal is …

This study will follow 100 adults with chronic liver disease who are hospitalized for sudden worsening of their condition. Researchers will track organ failure, recovery, and whether patients need a liver transplant or die within 6 months. The goal is to better understand how the…

This study will compare a new handheld device to the standard iLivTouch system for measuring liver stiffness and fat in 224 adults with chronic liver disease. Participants will be tested with both devices while lying down and sitting. The goal is to see if the handheld device is …

This study will screen 1,000 Chinese adults aged 18 to 50 living in Milan for hepatitis B and C using rapid finger-prick tests. Participants get counseling in Italian or Chinese, fill out a short questionnaire, and receive results the same day. The goal is to see if culturally ta…

This study will look at 150 infants and children aged 1 month to 4 years who are admitted to a hospital gastroenterology unit with a gastrointestinal disease. The goal is to find out how common electrolyte disturbances (like low sodium or potassium) are in these children. By meas…